| Objective: Tumor necrosis factor receptor related factor 1(TRAF1)regulates TRAF1-dependent signaling pathways and participates in various important cellular processes.Studies have shown that the expression of TRAF1 is up-regulated in non-small cell lung cancer tissues and plays an important role in tumor invasion,development and metastasis.However,the expression level of TRAF1 in serum of lung cancer patients is unclear.In this study,the enzyme-linked immunosorbent assay(ELISA)method was used to detect the expression level of serum TRAF1 in patients with stage III～IV lung cancer before and after chemotherapy and in healthy people,and to explore the clinical significance of TRAF1 in stage III～IV lung cancer.Methods: This research adopt the ELISA method to detect 60 patients with stage III～IV lung cancer and the same period of 60 cases of healthy subjects TRAF1 expression level in serum,compare the difference of serum TRAF1 expression between the lung cancer group and the healthy control group.To analyze whether there are differences in serum TRAF1 levels in patients with lung cancer in different clinicopathological characteristics such as gender,age,smoking status,pathological type,tumor location,TNM staging,etc.All 60 patients with lung cancer received 2 cycles of conventional chemotherapy,and the serum TRAF1 level was detected after chemotherapy and whether there was any difference compared with that before chemotherapy.The receiver operating characteristic curve(ROC)was used to calculate the area under the curve(AUC)to evaluate the diagnostic value of serum TRAF1 for lung cancer.Results:(1)The expression level of TRAF1 in serum of patients with lung cancer was significantly higher than that of healthy control group,and the difference was statistically significant(P<0.05).(2)There was no significant difference in the expression level of serum TRAF1 in different gender,age,smoking status,pathological type,bone metastasis,brain metastasis,and different tumor locations(left lung or right lung)(P>0.05).(3)The serum TRAF1 level of patients with stage IV lung cancer was significantly higher than that of stage III(P<0.05).(4)The serum TRAF1 level of advanced lung cancer patients after 2 cycles of chemotherapy was significantly lower than that before chemotherapy,and the difference was statistically significant(P<0.05);the serum TRAF1 of lung adenocarcinoma after chemotherapy was significantly lower than before chemotherapy,and the difference was statistically significant(P<0.05);the serum TRAF1 level of lung squamous cell carcinoma after chemotherapy was significantly lower than before chemotherapy,and the difference was statistically significant(P<0.05);the serum TRAF1 level of small cell lung cancer after chemotherapy was not significantly changed compared with that before chemotherapy,the difference was not statistically significant(P>0.05).(6)The AUC of ROC curve of serum TRAF1 in the diagnosis of lung cancer was 0.893 the best cut-off value of serum TRAF1 is113.68pg/ml,the sensitivity is 90%,and the specificity is 78.57%;the AUC of serum TRAF1 for the diagnosis of lung adenocarcinoma is 0.893,the sensitivity is 86.96%,and the specificity is 87.69%;the AUC for the diagnosis of lung squamous cell carcinoma is 0.886,the sensitivity is 70.83%,and the specificity is 94.64%;the AUC for the diagnosis of small cell lung cancer is 0.906,the sensitivity is 50%,and the specificity is 98%;the best cut-off value for the diagnosis of lung adenocarcinoma,lung squamous cell carcinoma,and small cell lung cancer were 130.78 pg/ml,98.62 pg/ml,and 74.68 pg/ml,respectively.Conclusions:(1)Serum TRAF1 may be related to the incidence of lung cancer and the severity of lung cancer.(2)Dynamic monitoring of serum TRAF1 level may be beneficial to the assessment of patients with lung cancer.(1)Serum TRAF1 may have potential diagnostic value for lung cancer,and can be used as a biomarker for the diagnosis of lung cancer. |
PDF Full Text Request